Abstract 248P
Background
Many patients concern the body imbalance after mastectomy and it is often cited as justification for immediate-breast reconstruction (IBR). However, few studies have investigated the impact of mastectomy or IBR on scoliosis, and analyzed only a small number of patients. We investigated whether mastectomy impacts spine alignment compared to IBR with a large cohort.
Methods
We retrospectively reviewed the patients who underwent breast cancer surgery between 2004 and 2018 at a single institution. Using the deep learning-based algorithm (DeepNoid Inc.), we collected Cobb's angle from chest posteroanterior x-rays at three time points: pre-operation, postoperative one-year, and five-years. Patients who underwent bilateral surgery, delayed-reconstruction, or LD-flap were excluded.
Results
Totally 6246 patients were included: 3442 (55.1%), 1911 (30.6%), and 893 (14.3%) patients underwent breast-conservation surgery (BCS), mastectomy without IBR, and IBR, respectively. At postoperative five-years, the mastectomy group showed the significantly greater change in Cobb's angle compared to both the BCS (p<0.001) and IBR (p=0.004) groups, while there was no significant difference between the BCS and IBR groups (p=0.347). After adjusting for other clinicopathologic variables, operation methods, adjuvant hormone treatments, and the direction of cancer remained significant factors affecting vertebral alignment. However, there was no relationship between the excised breast weights and Cobb's angle. Propensity score matching also showed that mastectomy group has greater change in angle compared to the other groups (vs. BCS, p=0.041; vs. IBR, p=0.047). Cobb’s angle was more evidence among patients under 50 years old (p=0.016) and who administered hormone treatment (p=0.009). Lastly, significantly more patients experienced lumbar pain after mastectomy (8.4%) than after BCS (6.7%) or IBR (4.1%) during the surveillance (p<0.001).
Conclusions
This is the largest study that showed the significant change in thoracic spine alignment after mastectomy compared to BCS and IBR. The results would provide the evidence on recommending breast reconstruction especially for young patients and educating post-mastectomy postural correction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Seoul National University Hospital.
Disclosure
H. Lee; W. Han: Financial Interests, Personal, Stocks or ownership, Not relevant to this study: DCGen. All other authors have declared no conflicts of interest.
Resources from the same session
54P - BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic biliary tract carcinoma (BTC)
Presenter: Zhihao Lu
Session: Poster session 13
55P - Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
Presenter: Arndt Vogel
Session: Poster session 13
56P - Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
Presenter: Federico Nichetti
Session: Poster session 13
57P - Integrative analysis of the genomic and transcriptomic landscape identifies ciliary genes as a therapeutic target in bile duct cancer
Presenter: Pietro Carotenuto
Session: Poster session 13
58P - Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
Presenter: Changhoon Yoo
Session: Poster session 13
59P - Prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: Results from the French prospective FFCD cohort
Presenter: Gael Roth
Session: Poster session 13
60P - Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study
Presenter: Lorenza Rimassa
Session: Poster session 13
61P - Addressing racial disparities in clinical trials in cholangiocarcinoma
Presenter: Abhinav Vyas
Session: Poster session 13
Resources:
Abstract
62TiP - HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
Presenter: Teresa Macarulla Mercade
Session: Poster session 13
240P - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Presenter: Michael Untch
Session: Poster session 13